Search
for
Sort by
Research 541–570 of 554
- Evaluation of Biological Activity Exerted by an Aza-bicyclocarboxylic acid Derivative using Anischemia-Reperfusion Injury Model
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Botulinum Toxins in Medical and Cosmetic Dermatology
- The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis
- Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance
- Hair Oils
- Comprehensive HPLC and UPLC-MS/MS Analysis for the Multi-component Detection of Hair Growth Compounds in Consumer Health Products
- Exploring the mechanism of Platycladi Cacumen in intervening androgenetic alopecia based on network pharmacology, molecular docking, and molecular dynamics simulation
- Heterozygous Variants of the SLC39A4 Gene and Possible Increased Risk for Developing Acrodermatitis Enteropathica with Kaposi’s Varicelliform Eruption
- Immunopharmacological potential of Arctium lappa L. in immune-mediated skin diseases: A critical review of experimental and clinical evidence
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
- Small Molecule Agents Against Alopecia: Potential Targets and Related Pathways
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- FDA approves label addition for PDE-5 inhibitor
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
- Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Lower Urinary Tract Symptoms: What’s New in Medical Treatment?
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Adverse effects of common medications on male fertility
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- Risks and side effects in the medical management of benign prostatic hyperplasia